Questions

551. Deputy Donna McGettigan asked the Minister for Health if she is aware of a serious complaint concerning the treatment of a child (details supplied) within CAMHS-ID, involving the discontinuation and withholding of clinically appropriate medication without clear justification; whether she will confirm if an investigation has been initiated; and if she will make a statement on the matter. [35988/26]

552. Deputy Donna McGettigan asked the Minister for Health the reason a formal complaint submitted in November 2025 regarding CAMHS-ID has not received a substantive response to date; the standard response timelines for such complaints; and the steps being taken to address delays in this case. [35989/26]

553. Deputy Donna McGettigan asked the Minister for Health the reason a request for full medical records from University Hospital Limerick, submitted in October 2025, has not yet been fulfilled; the statutory timeframe for such requests; and when the records will be released. [35990/26]

554. Deputy Donna McGettigan asked the Minister for Health the oversight mechanisms in place within CAMHS-ID to ensure clinical decisions, particularly those involving the withdrawal of psychiatric medication in vulnerable children, are evidence-based, documented and subject to review; and if she will outline any recent audits conducted in this area. [35991/26]

555. Deputy Donna McGettigan asked the Minister for Health the procedures in place where concerns are raised that a clinician has recorded or shared inaccurate clinical information; whether such cases are automatically referred for independent review; and the patient safety is protected in such circumstances [35992/26]

556. Deputy Donna McGettigan asked the Minister for Health whether there are safeguards to prevent inappropriate sharing or coordination of inaccurate patient information across different HSE departments; and if any investigation has been undertaken into such concerns within CAMHS services. [35993/26]

557. Deputy Donna McGettigan asked the Minister for Health the circumstances under which a clinician is referred to the relevant regulatory body following a complaint; whether any referrals have arisen from CAMHS-ID complaints in the past three years; and if she will provide details [35994/26]

558. Deputy Donna McGettigan asked the Minister for Health the actions that have been taken to address systemic failures within CAMHS following previous reviews and reports; and the measures that are in place to ensure that similar failures are identified and addressed promptly in other regions. [35995/26]

559. Deputy Donna McGettigan asked the Minister for Health whether she will commit to an independent investigation into serious patient safety concerns raised in relation to CAMHS-ID; and if not, the reason for that decision. [35996/26]

560. Deputy Donna McGettigan asked the Minister for Health the immediate steps that are taken when credible concerns are raised that a clinician may pose a risk to patient safety; whether such clinicians are subject to restriction or supervision pending investigation; and if she will make a statement on the matter. [35997/26]

561. Deputy Donna McGettigan asked the Minister for Health if she considers it acceptable that serious allegations concerning patient safety within CAMHS-ID can remain unaddressed for several months; and the actions she will take to ensure accountability in this case. [35998/26]

562. Deputy Ken O'Flynn asked the Minister for Health the total expenditure by the HSE in each of the years on the reimbursement of medicines prescribed for erectile dysfunction, including sildenafil and tadalafil; medicines prescribed for menopause-related conditions, including hormone replacement therapy products and topical vaginal oestrogen preparations, under the general medical services scheme, the drugs paymen…

563. Deputy Ken O'Flynn asked the Minister for Health if she will confirm whether service provision for early pregnancy loss is standardised across HSE hospital groups; and if she will provide any available comparative information on access to Early Pregnancy Units, diagnostic services, and medical management pathways between hospital groups. [36002/26]

564. Deputy Ken O'Flynn asked the Minister for Health the clinical pathways in place in each HSE maternity hospital and hospital group for the management of early pregnancy loss; whether medical management using pharmacological treatment including Misoprostol is available within each hospital group; and if she will provide a breakdown of the models of care in operation (including expectant, medical and surgical manag…

565. Deputy Ken O'Flynn asked the Minister for Health the number and location of early pregnancy units or equivalent dedicated early pregnancy assessment services within the HSE maternity hospital system in each of the past five years, if she will outline any hospitals without access to a dedicated early pregnancy assessment service; and if she will make a statement on the matter. [36004/26]

566. Deputy Ken O'Flynn asked the Minister for Health the number of recorded cases of early pregnancy loss managed within HSE maternity hospitals ; and the number of cases managed by expectant management, medical management including pharmacological treatment such as Misoprostol, and surgical intervention; and if she will provide a breakdown by hospital group, in each of the years 2021 to 2025 and to date in 2026, in…

567. Deputy Ken O'Flynn asked the Minister for Health whether any monetary approval thresholds exist within the treatment abroad scheme requiring additional sign-off for high-cost procedures; the officials or grades responsible for such approvals; and if she will provide the thresholds currently applied. [36018/26]

568. Deputy Ken O'Flynn asked the Minister for Health whether the treatment abroad scheme operates any formal value-for-money assessment process prior to approving exceptionally high-cost procedures abroad; and if so, the methodology used. [36019/26]

569. Deputy Ken O'Flynn asked the Minister for Health the number of Treatment Abroad Scheme applications approved with an estimated cost exceeding in each year since 2020 (details supplied). [36020/26]

570. Deputy Ken O'Flynn asked the Minister for Health whether any applications under the Treatment Abroad Scheme have been refused wholly or partly on financial, budgetary, or proportionality grounds since 2020; and if she will provide annual figures. [36021/26]

571. Deputy Ken O'Flynn asked the Minister for Health whether the HSE maintains a central register of high-cost overseas procedures approved under the Treatment Abroad Scheme; and if so, the governance and reporting arrangements applying to that register. [36022/26]

572. Deputy Ken O'Flynn asked the Minister for Health the dates of all internal audit reviews, Comptroller and Auditor General examinations, or other formal oversight reviews conducted in respect of the Treatment Abroad Scheme since 2020; and if copies of findings or recommendations will be provided. [36023/26]

573. Deputy Ken O'Flynn asked the Minister for Health whether any risk assessment has been conducted regarding financial exposure arising from exceptionally high-cost procedures funded under the Treatment Abroad Scheme; and if so, whether she will provide details. [36024/26]

574. Deputy Ken O'Flynn asked the Minister for Health whether the Treatment Abroad Scheme has any specific governance pathway for novel, experimental, or highly specialised procedures abroad involving significant State expenditure. [36025/26]

575. Deputy Ken O'Flynn asked the Minister for Health whether the Treatment Abroad Scheme maintains procedure-specific coding or categorisation for any surgical specialties funded abroad; and if so, to provide the categories recorded. [36026/26]